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ACUTE SYSTEMIC ADMINISTRATION OF MORPHINE SELECTIVELY INCREASES MU OPIOID 
RECEPTOR BINDING IN THE RAT BRAIN 
James W. Lewis, Michael E. Lewis, Deborah J. Loomus, and Huda Akil. Mental 
Health Research Institute and Department of Psychiatry, University of 
Michigan, Ann Arbor, MI, 48109, U.S.A. (reprint requests to JWL). 
Opioid receptor binding, including the mu, delta, and kappa receptor 
subtypes, was compared in morphine-injected and control rats. Brain tissues 
were homogenized and centrifuged either one or two times prior to receptor 
binding assay. In brain membranes from morphine-injected rats centrifuged 
once, there was a decrease in mu, but not delta or kappa, binding compared to 
controls, perhaps indicating occupation of these sites by morphine. By 
contrast, homogenates from morphine-injected rats centrifuged twice 
manifested an increase in mu, but not delta or kappa, binding sites. These 
results suggest that pharmacological stimulation of central opioid receptors 
with morphine causes a rapid, selective increase in the number of available 
mu binding sites. 
INTRODUCTION 
It is now widely held that multiple subtypes of opioid receptors 
mediate the various physiological and behavioral effects of endogenous and 
exogenous opioids (for recent reviews see 1,210 A common theme in the 
description of multiple receptor subtypes is the attempt to ascribe 
particular functions to specific receptors (e-g. 3,4). Converging lines of 
evidence, from a variety of in vitro bioassays, receptor binding assays, and -- 
in vivo pharmacological studies, points to an important role for the mu -- 
receptor in mediation of analgesia (e.g. 5-7). There are, however, reports 
that kappa and delta selective agents can also induce analgesia depending 
upon variables such as the route of administration and the type of pain 
inhibited (e.g. 7). In the present study, we have shown that morphine, the 
prototypic opiate analgesic and mu receptor agonist, selectively occupies mu 
opioid receptors in vivo following administration of pharmacologically 
relevant doses. Interestingly, following systemic administration of 
analgesic doses of morphine, a pronounced increase in the number of mu, but 
not delta or kappa, binding sites was observed. 
ME'IHODS 
Subjects were male Sprague-Dawley rats (200-25Og; Charles River 
Laboratories, Worcester,MA). Rats were injected subcutaneously with either 
morphine sulfate (5 mg/kg) or 0.9% saline 20 min prior to sacrifice by 
decapitation. Brains (minus cerebellum) were rapidly removed, placed in ice 
cold Tris buffer (50 mM, pB 7.4), and homogenized with a Brinkmsn Polytron. 
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Final tissue concentration was 50 mg wet weight/ml Tris. Homogenates were 
then centrifuged (15 min, 27,000 x g> and the pellet resuspended in Tris 
buffer. Subsequently, half of each homogenate was centrifuged a second time 
in order to wash the tissue further prior to the binding assay. Th receptor 
binding was carried out in a volume of 0.25 ml comprising 0.05 ml [ 5 ]-ligand 
(concentrations ranging from 0.5-40 nM), 0.050 ml of Tris or 2 micromolar 
unlabelled ligand (to determine total and non-specific binding, 
respectively), and 0.15 ml of brain homo enate. 
% 
Binding of each of the 
opioid receptor subtypes was defined using [. ]-D-Ala2-MePhe4_enkephalin- 
g YOl5 
4 
(DAGO; RX783006, Amersham, 30 Ci/mmole) for mu binding, 
[ ]-D-Ser2-D-Thr6-Leucine enkephalin (DSLET; New England Nuclear, 30.5 
Ci/mmole), and [3H]-b remazocine (New England Nuclear, 30.5 Ci/mmole) in the 
presence of 100 or 1000 nM unlabelled DAGO and DSLET for kappa binding (8). 
The receptor assay mixture was incubated on ice for 90 min in 96 well 
microtiter plates, filtered under vacuum on Schleicher and Schuell #32 glass 
fiber filters using a Brandel cell harvester, and the filters counted in a 
liquid scintillation counter. 
Data for analysis were obtained in two ~ys. For production of 
Scatchard plots, brains of three rats in each injection condition were pooled 
and the homogenate was assayed with radiolabelled ligands in concentrations 
ranging from 0.05 nM to 40 nM. Data from this experiment were analyzed using 
the computer program LIGAND (9) to obtain best fit estimates of the binding 
parameters KD and B,,. For statistical comparison of the observed 
differences in binding between saline and morphine-injected groups, brains of 
individual rat 
$ 
from each group (n-6) were assayed with 0.5 and 5.0 nM of 
each of the [ ] ligands, and following one or two centrifugations. Group 
differences were tested using analysis of variance with repeated measures and 
Newman-Keuls tests for specific comparisons. A significance level of p < .Ol 
was used for all inferential statistics. 
RESULTS 
Morphine caused an apparent decrease in the binding capacity of brain 
membranes for the mu, but not the delta or kappa, ligands (Table 1) indicated 
by the observed decrease in the apparent KD after one centrifugation. That 
this difference represents receptor occupation by morphine is consistent with 
classically defined competitive binding models. There was, however, an 
accompanying increase in B,,. After the second centrifugation, membranes 
from morphine-injected brains showed a marked increase in the total number of 
mu, but not delta or binding sites (Table 1). In this case, the 
apparent KDs for [ r-%GO $ binding are similar in control and 
morphine-injected homogenates suggesting successful elimination of bound 
morphine and the remaining effect being a marked increase in B,,. 
Analysis of the data from animals assayed individually revealed the 
reduction of in vitro binding to be mu selective and statistically reliable. 
Moreover, the apparent increase mu binding in membranes centrifuged twice 
from morphine-injected rats was also significant and specific to the mu 
receptor. 
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Table 1. EFFECT OF MORPHINE (5 mg/kg) ON OPIOID RECEPTOR BINDING. 
KD (nM) B (fmoleslmg) 
CON MOR %CON maCCN MOR XCON 
MU 1 SPIN 1.3+.1 2.1+.3 162 13.2+.4 16.4+.1 124 
2 SPINS 1.1+.1 1.2+.1 109 11.3+.5 15.1+.4 134 
DELTA 1 SPIN 3.1+.4 3.1+. 5 100 12.7+.8 11.8+.9 93 
2 SPINS 3.4+.3 3.8+.3 112 11.4+.5 12.9+.6 113 
KAPPA* 1 SPIN .4+.05 .4+. 03 100 2.2+. 1 2.1+.1 95 
2 SPINS .4+.03 .4+.03 100 1.9+. 1 1.9+.1 100 
Data presented are best fit parameter estimates + S.E.M dervived from the 
LIGANDprogram. ontrol=CON, Morphine-injected=MOR, Percent of Control=%CON. 
* Analysis of [ $ ]-Breorazocine binding indicated the presence of 2 sites. 
These data represent only the high affinity site. 
DISCUSSION 
Examination of receptor binding properties of brain tissue from 
morphine-injected rats following homogenization and either one or two 
centrifugations illustrates two points. First, when binding is done in 
tissue centrifuged once, to remove endogenous opioids liberated by 
homogenization and non-receptor associated morphine, there appears to be a 
significant occupation of mu, but not delta or kappa, sites. After the 
second centrifugation, which presumably washes off receptor-bound morphine, 
it is revealed that systemic administration of morphine appears to have 
caused a rapid, substantial (approximately 35%)) and selective increase in 
b ain mu opioid receptors. 
[$ ]-ligands, 
The present results, by the use of selective 
confirm and extend the original observation of this phenomenon 
by Pert and Snyder (IO). 
In recent work attempting to elucidate the mechanism of this apparent 
increased number of mu receptors we have made the following observations: 1) 
This phenomenon is general in that it occurs in spinal cord as well as brain, 
but is specific in that it appears not to be elicited by non-mu opioid 
agonists (e.g. the kappa selective drug U-50 488H). 2) In vivo labelling of -- 
mu receptors by systemic administration of [ a]-etorphine (lo-40 micro-(X/kg; 
see 6) is enhanced by co-administration of a low dose of morphine suggesting 
increased receptor availability. 3) The effect is rapid in onset (10 min; 
see also reference lo), dose dependent (maximal at lo-20 mg/kg), and of 
prolonged duration (maximal at 1 hr and still significant up to 3 hr after 
morphine injection). 
Several hypotheses which could account for the apparent 
receptor-inducing effects of morphine. It may be that many mu receptors are 
tonically occupied by an endogenous ligand that is displaced, in viva, by 
morphine. Perhaps this ligand, present on the receptors of saline-injected 
animals and not as easily eliminated as morphine during the brain homogenate 
preparation, remains throughout the binding assay effec ively masking mu 
sites. Thus, more mu receptors may be available to the [ 4-i ]-ligands during 
the assay in membranes from morphine-injected rats. Alternatively, 
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stimulation of opioid systems by morphine may cause the activation of 
normally inert receptors; possibly via insertion of soluble receptors into 
membranes or enzymatic activation of dormant receptors (e.g. 11). Although 
many questions remain regarding the underlying physiological mechanisms and 
behavioral significance of this phenomenon, taken together our results 
suggests that systemic administration of opiates causes profound alterations 
in the binding characteristics of central nervous system opioid pathways. 
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